Stock Screener App

Frei -

Installieren

18.44

1.60% -0.30

Damora Therapeutics Inc (DMRA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten

Breaking News about Damora Therapeutics, Inc.Ordinary Shares (Nasdaq:DMRA) - FinancialContent

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares - Investing.com

Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com South Africa

Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com India

Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net

Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn

Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn

DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan

Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com

Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st

Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st

Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm

Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn

Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneDark Pool Volume - dars.gov.et

Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et

Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesFear Greed Index - vinanet.vn

Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesSuperTrend - careplusvn.com

Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - kalkinemedia.com

Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan

Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan

DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn

Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat

Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan

Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha

RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo

DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus

Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade

Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade

Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan

Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times

Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan

Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st

DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresQuarterly Earnings - vinanet.vn

Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan

Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com

Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com

Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times

Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com UK

Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan

Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India

Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com Australia

Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com

DMRA Q2'26 Earnings: EPS estimate is (0.41) USD - TradingView

DRTS

$12.29

6.61%

IAM

$23.81

0.00%

SNDX

$12.90

5.49%

BCAX

$16.78

4.77%

OMER

$16.20

13.78%

TSHA

$3.62

2.95%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters